BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small molecule drugs. The company is headquartered in Durham, North Carolina.
| Revenue (TTM) | $940.61M |
| Gross Profit (TTM) | $727.92M |
| EBITDA | $433.65M |
| Operating Margin | 45.10% |
| Return on Equity | -1925.00% |
| Return on Assets | 52.90% |
| Revenue/Share (TTM) | $4.10 |
| Book Value | $-1.78 |
| Price-to-Book | 56.59 |
| Price-to-Sales (TTM) | 2.65 |
| EV/Revenue | 3.114 |
| EV/EBITDA | 7.17 |
| Quarterly Earnings Growth (YoY) | 1400.00% |
| Quarterly Revenue Growth (YoY) | 33.60% |
| Shares Outstanding | $255.53M |
| Float | $222.41M |
| % Insiders | 1.20% |
| % Institutions | 105.38% |
Volatility is currently expanding
The consensus price target hints at a 98.7% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Investors need to pay close attention to BCRX stock based on the movements in the options market lately.
BioCryst Pharmaceuticals (NASDAQ:BCRX) closed at $9.84 on August 10, 2026, giving the Durham-based rare-disease specialist a market cap of roughly $2.5 billion.
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2026 Earnings Call Transcript
BioCryst Pharmaceuticals NASDAQ: BCRX reported second-quarter results marked by growth in ORLADEYO revenue, the start of shipments for its pediatric oral-pellet formulation, and completion of enrollment in its pivotal navenibart trial for hereditary angioedema, or HAE.
BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $0.3 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.15 per share a year ago.
— Total net revenue of $218.3 million and ORLADEYO ® net revenue of $158.2 million — — Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 million — — Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $690 million to $715 million — — Began shipping ORLADEYO oral pellets to pediatric patients on August 3 — — Completed enrollment in ALPHA-ORBIT, the ongoing pivotal study of navenibart — RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the quarter ended June 30, 2026, and provided a business update.
RESEARCH TRIANGLE PARK, N.C., July 22, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2026 financial results on Wednesday, August 5, 2026.
RESEARCH TRIANGLE PARK, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) (“BioCryst” or the “Company”) today announced the appointment of David W. Jenkins, MA, PhD, to the newly created position of Chief Scientific Officer, effective immediately, reporting to Dr. Sandeep Menon, Chief Research and Development Officer. In this role, Dr. Jenkins will build and lead an efficient research team focused on leveraging external innovation, capabilities and partnerships to accelerate the delivery of transformative rare disease therapies to patients. He will be based in the Company's Boston office.
The consensus price target hints at an 118% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BCRX and any ticker you trade — then tracks every position and per-strategy win rate.
